Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.58 |
| ▸ | APLNR | P35414 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 5/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30358622 | 0.82 | OPRD1 (0.61) | APLNROPRD1OPRM1OPRK1NTSR1 | |
| SCHEMBL29362706 | 0.81 | GRB2 (0.67) | GRB2APLNRNTSR1NTSR2SORT1 | |
| SCHEMBL29392907 | 0.80 | NTSR1 (0.57) | OPRD1OPRM1OPRK1NTSR1NTSR2 | |
| SCHEMBL29551878 | 0.80 | OPRD1 (0.56) | APLNROPRD1OPRM1OPRK1NTSR1 | |
| SCHEMBL30411733 | 0.80 | GRB2 (0.54) | GRB2OPRD1OPRM1OPRK1NTSR1 | |
| SCHEMBL30844298 | 0.79 | GRB2 (0.57) | GRB2APLNROPRM1OPRK1NTSR1 | |
| SCHEMBL31257010 | 0.79 | XIAP (0.57) | GRB2NTSR1NTSR2SORT1 | |
| SCHEMBL29445609 | 0.78 | F2 (0.57) | GRB2APLNRNTSR1NTSR2F2 | |
| SCHEMBL30997450 | 0.78 | GRB2 (0.55) | GRB2OPRM1NTSR1NTSR2SORT1 | |
| SCHEMBL30772337 | 0.77 | GRB2 (0.54) | GRB2APLNROPRM1OPRK1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646228-A1 | ETHER OF PHOSPHATIDYLCHOLINE AND PHOSPHATIDYLETHANOLAMINE, THEIR LYSO-FORMS AND MIXTURE THEREOF FOR USE IN THE TREATMENT OF A DISEASE OR DISORDER CAUSED BY A DEFICIENCY IN PLASMALOGENS | Baker Heart and Diabetes Institute (AU) | 2025-11-12 | — | — | EP | disclosed |
| EP-4582540-A1 | METHOD FOR PRODUCING NUCLEIC ACID MOLECULE | Genedesign, Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| CN-120202295-A | Method for producing nucleic acid molecule | 基因设计有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20240379235-A1 | MULTI-OMIC PREDICTION MODEL FOR METASTATIC PROSTATE CANCER | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2024-11-14 | — | — | US | disclosed |
| WO-2024192471-A1 | METHODS OF ASSESSING METABOLIC HEALTH | Baker Heart and Diabetes Institute (AU) | 2024-09-26 | — | — | WO | disclosed |
| WO-2024148052-A1 | ETHER OF PHOSPHATIDYLCHOLINE AND PHOSPHATIDYLETHANOLAMINE, THEIR LYSO-FORMS AND MIXTURE THEREOF FOR USE IN THE TREATMENT OF TREATMENT OF A DISEASE OR DISORDER CAUSED BY A DEFICIENCY IN PLASMALOGENS | Baker Heart and Diabetes Institute (AU) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024048684-A1 | METHOD FOR PRODUCING NUCLEIC ACID MOLECULE | 株式会社ジーンデザイン | 2024-03-07 | — | — | WO | disclosed |
| US-20230348944-A1 | LACTOSE CONVERTING ALPHA-1,2-FUCOSYLTRANSFERASE ENZYMES | INBIOSE N.V. (BE) | 2023-11-02 | — | — | US | disclosed |